Cardio Metabolic Centre

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease2 trials
• Obesity2 trials
• Stroke2 trials
• Coronary artery disease1 trial
• Heart failure1 trial
• Peripheral artery disease1 trial
• Type 2 diabetes1 trial

Phase

• Phase 33 trials

Status

• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Amgen Inc.1 trial

Running trials

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Stroke1 recruiting